Introduction
by chronic anovulation, hyperandrogenaemia and sometimes hyperinsulinaemia (Dunaif, 1999) , is the most common cause Chronic anovulation constitutes a major proportion of infertile of normogonadotrophic normo-oestrogenic anovulatory incouples (20-25%) (van Santbrink et al., 1997) . According to fertility. Certainly, PCOS is part of the WHO 2 group, with a the World Health Organization (WHO) (Rowe et al., 2000) , variable reported incidence based on differences in inclusion anovulatory patients are classified on the basis of two endocrine criteria used (van Santbrink, 1997) . A previous National parameters, the concentrations of endogenous gonadotrophins Institute of Health (NIH) consensus workshop concluded, but and oestrogens. Approximately 80% of patients suffering from by no means unanimously, that hyperandrogenaemic chronic chronic anovulation present with serum FSH concentrations anovulation should be considered the hallmark criterion for within the normal range in combination with some endogenous the diagnosis of PCOS (Dunaif et al., 1992) . More recently, it oestrogen activity. These women are classified as normowas reported (and agreed by the last NIH consensus workshop) gonadotrophic normo-oestrogenic anovulatory infertility, more that the occurrence of polycystic ovaries should be added commonly referred to as WHO 2 (Rowe et al., 2000) . Since (Dewailly, 2000) . aetiological factors underlying this condition may vary from Inhibin is a dimeric non-steroidal glycoprotein hormone that one patient to another, WHO 2 anovulatory women constitute selectively inhibits FSH production and/or release from the a notoriously heterogeneous population.
The polycystic ovarian syndrome (PCOS), characterized pituitary. It consists of two partially homologous sub-units, developing small antral follicles during the early follicular phase (Groome et al., 1996) . Recent reports on serum and follicular fluid inhibins in PCOS are conflicting. According to some authors, concentrations of total immunoreactive inhibins (Mizunuma et al., 1994) , α inhibin (Pigny et al., 1997 ), or inhibin B (Lambert-Messerlian et al., 1994 Anderson et al., 1998; Lockwood et al., 1998) are raised. Others found normal concentrations of total immunoreactive inhibin (Buckler et al., 1988; Pache et al. 1992) or inhibin B (Magoffin and Jakimiuk, 1998). Since inhibin B selectively inhibits FSH, high inhibin B could be held responsible for an elevated LH/FSH ratio characteristic for some patients (Magoffin and Jakimiuk, 1998) . Moreover, inhibin may directly stimulate theca cell androgen biosynthesis (Hillier et al., 1991) . Inhibin B concentrations might also represent the extent of ovarian dysfunction in these patients, since an increased number of healthy follicles (Hughesdon, 1982; Pache et al., 1991a) may result in increased limits (1-10 IU/l) (van Santbrink et al., 1995; Schipper et al., 1998) , % Amenorrhoea 25 29 Cycle length (days) 60 (35-199) 75 (35-199) (iv) positive withdrawal bleeding after progestagen administration in EUB-415; Hitachi Medical Corporation, Tokyo, Japan) was used. The ovaries were localized and scanned as described previously a PCOS based on hyperandrogenaemia [free androgen index (FAI) Ͼ4.5] and (Pache et al., 1991b) . Ovarian volume, stroma echogenicity (arbitrarily polycystic ovaries (mean ovarian volume Ͼ 10.8 m).
scored from 1 to 3 per ovary) as well as the mean follicle number b Defined as increased mean ovarian volume (Ͼ10.8 ml) and an increased number of follicles per ovary (Ͼ10).
were assessed as described earlier (van Santbrink et al., 1997) .
BMI ϭ body mass index; DHEA-S ϭ dehydroepiandrosterone sulphate;
The control group consisted of 30 healthy volunteers selected by SHBG ϭ sex hormone binding globulin.
advertisement and paid for participation as previously published (Schipper et al., 1998) . Inclusion criteria were a regular menstrual α combined with either βA (inhibin A) or βB (inhibin B)
cycle (26-30 days), 20-35 years of age, normal body mass index (Robertson et al., 1997) . Recently, it was reported that inhibin (BMI 18-25 kg/m 2 ) and no previous use of medication or oral A serum concentrations are high around ovulation and during contraceptives during at least 3 months prior to the study. Transvaginal the mid-luteal phase of the normal menstrual cycle. In contrast,
ultrasound and blood sampling were performed during the early follicular phase (cycle day 3, 4 or 5).
inhibin B seems to be the predominant form secreted by Similarly, co-variance analysis revealed that the interrela- (Schipper et al., 1998) . The detection limit of the assay, defined as tionship between inhibin B, LH, testosterone, and androstenethe amount of inhibin equivalent with the signal of the blank ϩ3 dione was mainly determined through the serum LH SDs of this signal, was 3.4 ng/l. Intra-and inter-assay coefficients of concentration (data not shown).
variation for inhibin B were Ͻ9 and 15% respectively.
In WHO 2 patients polycystic ovaries on ultrasound exam- also presented with increased concentrations of LH and/or increased testosterone. Similarly, 43% of all WHO 2 patients Results showed elevated serum concentrations of LH and/or testosterone in combination with polycystic ovaries on ultrasound. In Normo-ovulatory controls (n ϭ 30) presented with a median PCOS patients, elevated serum LH concentrations were found age of 29 years (range 20-35 years), median cycle duration in 58% of all individuals whereas elevated serum inhibin B of 28 days (range 25-32 days) and median BMI of 21.4 kg/m 2 concentrations were found in only 23% of all cases. An (range 18.9-24.2 kg/m 2 ). The upper limit of normal inhibin B elevated testosterone plasma concentration was observed in was 213 ng/l (95th percentile) and the lower limit (5th percentile) was 22 ng/l (Figure 1) . Medians of inhibin B on 35% of PCOS patients. 
Discussion
shown). Moreover, differences in inhibin B concentrations in control subjects (Anderson et al., 1998) might be due to the The data presented here in 379 normogonadotrophic oligomenorrheic patients indicate that overall inhibin B serum smaller number of regularly cycling women (n ϭ 10 and 5 respectively) compared with the current study (n ϭ 30). concentrations are elevated neither in the total group of WHO 2 women nor in the subgroup of PCOS patients. 'High' inhibin Finally, inhibin B is secreted in a pulsatile fashion (Lockwood et al., 1998) which may affect the accuracy of single blood B concentrations reported in previous studies (Anderson et al., 1998; Lockwood et al., 1998) were well within the normal withdrawal. Besides, one study (Lockwood et al., 1998) included only clomiphene-resistant women, which might range of regularly cycling women in the current study. This discrepancy in absolute values might be due to modifications in represent a different subset of patients. Dominant follicle selection is disturbed in polycystic ovaries, the assay that may affect absolute concentrations (N.P.Groome, personal communication). In one study (Lockwood et al., resulting in an increased number of follicles per ovary and presumably a variable number of healthy early antral follicles 1998), inhibin B concentrations were assessed on day 5 of the menstrual cycle in contrast to the current study, in which they (Fauser, 1994) . Because inhibin B is produced predominantly by healthy small follicles it has been postulated that inhibin were measured on day 3. However, inhibin B shows only modest changes at the beginning of the cycle (Groome et al., B concentrations are increased in at least some PCOS patients. Elevated concentrations of inhibin B could be established in 1996). In the current series, inhibin B serum concentrations were similar on day 3 compared to days 4 or 5 (data not two preliminary reports (Anderson et al., 1998; Lockwood et al., 1998) in 9 and 10 PCOS patients respectively. In exerts limited negative feedback on pituitary FSH production at the beginning of the cycle. Moreover, intra-follicular inhibin contrast, in the present study, inhibin B concentrations in PCOS patients were similar compared with WHO 2 and B concentrations in PCOS do not significantly decrease with increasing follicle diameters also indicating that FSH is the control patients.
It has also been postulated that most of the inhibin B primary drive of the feedback (Lambert-Messerlian et al., 1997) . produced in the ovary during the follicular phase originates from the dominant follicle due to the observed major differ-
In conclusion, inhibin B serum concentrations are normal in most normogonadotrophic anovulatory infertile women, ence in the amount produced by large antral follicles (with androstenedione/oestradiol ratios ഛ4) compared with remainincluding PCOS, suggesting a normal number of healthy early antral follicles despite increased overall follicle numbers in ing cohort follicles with androstenedione/oestradiol ratios Ͼ4 (Magoffin and Jakimiuk, 1998). Follicular fluid oestradiol, PCOS. Serum inhibin B assays cannot be recommended for routine screening in normogonadotrophic anovulatory inferandrostenedione and total immunoreactive inhibin concentrations as well as androstenedione/oestradiol ratios were similar tility. in PCOS patients compared to controls (Pache et al., 1992) . More recently, inhibin B concentrations in these 4-8 mm References follicles from polycystic ovaries were also found to be similar concentrations of androstenedione (Pigny et al., 1997 
